Baricitinib (Olumiant™) is an orally-administered, small-molecule, janus-associated kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus. JAKs transduce intracellular signals from cell surface receptors for various cytokines and growth factors involved in inflammation and immune function, suggesting JAK inhibitors may be of therapeutic benefit in inflammatory conditions. In February 2017, baricitinib was approved in the EU, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Regulatory approval to market baricitinib as a treatment for RA has also been sought in the USA and Japan. This article summarizes the milestones in the development of baricitinib leading to this first global approval for the treatment for moderate to severe active RA in adult patients who have responded inadequately to, or are intolerant to one or more DMARDs.
KeywordsSystemic Lupus Erythematosus Atopic Dermatitis Adalimumab Herpes Zoster Diabetic Kidney Disease
The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis, Springer SBM.
- 1.Eli Lilly and Company, Incyte Corporation. European Commission approves once-daily olumiant tablets for treatment of adults with moderate-to-severe active rheumatoid arthritis [media release]. 13 Feb 2017.Google Scholar
- 2.Eli Lilly and Company, Incyte Corporation. US FDA extends review period for baricitinib, an investigational rheumatoid arthritis treatment [media release]. 13 Jan 2017.Google Scholar
- 3.Eli Lilly and Company, Incyte Corporation. Lilly and Incyte announce collaboration for development and commercialization of oral anti-inflammatory and autoimmune therapies [media release]. 21 Dec 2009.Google Scholar
- 6.European Medicines Agency. Baricitinib (Olumiant): summary of product characteristics 2017. http://ec.europa.eu/health/documents/community-register/2017/20170213136870/anx_136870_en.pdf. Accessed 17 Feb 2017.
- 12.Takeuchi T, Genovese M, Xie L, et al. Baricitinib dose step-down following disease control in patients with rheumatoid arthritis [abstract no. OP0228]. Ann Rheum Dis. 2016;75(Suppl 2):144.Google Scholar
- 14.Keystone E, Taylor P, Genovese M, et al. Safety and efficacy of baricitinib through 128 weeks in an open-label, long-term extension study in patients with rheumatoid arthritis [abstract no. 67]. J Rheumatol. 2015;42(7):1292.Google Scholar
- 16.Tanaka Y, Emoto K, Cai Z, et al. Efficacy and safety of baricitinib in Japanese rheumatoid arthritis patients during a 52 week extension phase [abstract no. 1483]. Arthritis. Rheumatol. 2014;66(Suppl 10):S652.Google Scholar
- 18.Papp K, Menter A, Raman M, et al. A Phase 2b dose-ranging trial of baricitinib, an oral JAK 1/JAK 2 inhibitor, in patients with moderate-to-severe psoriasis: Results from the randomized withdrawal and re-treatment periods [abstract no. P032]. J Invest Dermatol. 2015;135(Suppl 3):S7.Google Scholar
- 19.Tuttle KR, Brosius III FC, Adler SG, et al. Baricitinib in diabetic kidney disease: results from a phase 2, multicenter, randomized, double-blind, placebo-controlled study [abstract no. 114-LB]. Diabetes. 2015;64(Suppl 1):LB29.Google Scholar